Golden rules for registrars
Medico-legal adviser Dr Jim Rodger offers some expert advice on how to excel as a GP registrar. Read more
More information on how the drug compares to diet and exercise, orlistat and sibutramine with regards to cost effectiveness is needed from manufacturers Sanofi Aventis, claimed NICE in a draft technology appraisal issued last week.
NICE also wants an assessment of the drug using the 5 per cent weight loss continuation rule to treatment with rimonabant at three, six, nine and 12 months.
Jeni Wilson, head of communications at Sanofi Aventis said: 'The consultation document represents the preliminary feedback of the appraisal committee and is not formal guidance on this technology.
'The preliminary thoughts of the committee may change after consultation.'
Comment below and tell us what you think
Quick search - use * for an abbreviated search, eg nico*
Medico-legal adviser Dr Jim Rodger offers some expert advice on how to excel as a GP registrar. Read more
Dr Kingsley Poole describes the differences he experienced working at a remote practice in New Zeala... Read more
Most people feel nervous facing an audience, but practice will make it easier, says Dr Kevin Brown. Read more
Contributed by Dr Charlie Easmon specialist adviser in travel medicine and medical director at The N... Read more
Contributed by Mr Ranan DasGupta, specialist registrar and Mr Jonathon Olsburgh, consultant urologic... Read more
By Dr Helen Hosker, GP and clinical commissioning lead for stroke, NHS Manchester, and Dr Pippa Tyrr... Read more
Leo Pharma has launched Xamiol gel, a combination of calcipotriol + betamethasone, for the treatment... Read more
Bayer HealthCare has launched Xarelto (rivaroxaban) for the prevention of venous thromboembolism in ... Read more
Wyeth has launched Torisel (temsirolimus), a first-line treatment for advanced renal cell carcinoma ... Read more
Comments
Only registered users may comment. Log in now or register for a free account.